System-IGF-1 Pathway and Alzheimer's Disease
- Conditions
- Alzheimer's DiseaseMild Cognitive ImpairmentControl With Normal Activities of Daily LivingCognitive Function 1, Social
- Registration Number
- NCT00647478
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Brief Summary
The aim is to assess the relationship between levels of IGF-I system components and cognitive status in patients with Alzheimer's disease (AD), in elderly subjects with normal cognitive function, and in patients with mild cognitive impairment (MCI).
- Detailed Description
AD is the most common cause of dementia. During aging, decline of biological brain functions due to a number of genetic and environmental factors facilitates the onset of AD. MCI includes prodromal AD.
The identification of the risk factors for AD must be a priority in order to define the best therapeutic approach.
Recent data support the notion that IGF-I pathway accounts for neuronal protection, with a dual effect, on both brain Aβ peptide and tau protein.
This large, multicenter, prospective, observational, cross-sectional population-based study in 3 parallel groups (200 participants per group) is aimed to assess differences between IGF-I and IGFBP3 circulating levels and polymorphisms in AD patients and control elderly subjects, and in MCI patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 693
Caucasian patients after a comprehensive geriatric assessment and giving informed written consent.
- In each arm :
- elderly subjects with normal cognitive function,
- patients with dementia of AD type (DSM-IV and NINCDS-ADRDA criteria),
- patients with MCI (European Consortium on Alzheimer's Disease, EADC).
Non AD dementia Major depression Use of anticholinesterase agent All diseases or major sensory deficits or any condition that might interfere with cognitive assessment and study objectives
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Circulating IGF-I and IGFBP-3 levels in AD patients and control elderly subjects at the time of assessment(T0). 24 hours
- Secondary Outcome Measures
Name Time Method Circulating IGF-I and IGFBP-3 levels 24 hours Genetic polymorphisms in IGF-I / IGFBP-3 24 hours Circulating IGF-I and IGFBP-3 levels and genetic polymorphisms in IGF-I / IGFBP-3 according to cognitive function. 24 hours
Trial Locations
- Locations (1)
Broca Hospital Memory Clinic (CMRR)
🇫🇷Paris, France